Selected Brain Tumor Related Abstracts from ASCO
نویسندگان
چکیده
Number Treatment NumberOfPatients PatientCatagory Outcome 13014 Accelerated RT/Temodar 28 New GBM mPFS=6m, PFS6=48%, OS1yr=48%, OS2yr=8%. 2051 AMG-102 20 Recurrent GBM Response rate = 30% 13010 Avastin + chemo 34 Recurrent GBM PSF6=25%, mTTP=4m, mOS=7.5m. 2021 Avastin + CPT-11 35 Recurrent GBM PFS6=43%, OS6=74%, 2yrOS=15%. 2023 Avastin + CPT-11 44 Recurrent GBM mPFS=5.2m, mOS=9.0m. 13000 Avastin + CPT-11 54 Recurrent high grade glioma mPFS=5m, mOS=9m. 2074 Avastin + daily Temodar 32 Recurrent GBM Response rate = 75% 13008 Avastin + Tarcevar 25 Recurrent GBM PFS6=24%; Response rate = 48%. 13007 Avastin 4 mg/kg 44 Recurrent GBM Response rate = 84%; Median duration of PR =3m. 2011 CDX-110 + Temodar 21 New GBM with EGFRvIII mPFS=16.6m, mOS not reached. 2017 cetuximab 55 recurrent high-grade glioma mPFS=1.9m, mOS=5.0m, PFS6=10%, OS6=40% 2056 cetuximab + Avastin + CPT-11 32 Recurrent GBM mTTP=6m; no better than Avastin + CPT-11 2077 cetuximab + RT/Temodar 17 New GBM 1yrOS=87%, PFS6=81%, PFS1yr=37%. 2005 Enzastaurin vs CCNU Phase III 397 Recurrent GBM Enzastaurin not superior than CCNU 2079 Fotemustine 43 Recurrent GBM PFS6=21%, mOS=6.0m. 2088 gefenitib + rapamycin 18 Recurrent GBM Response rate = 44% 13018 Nimustine + teniposide 35 Recurrent GBM PFS6=28%, mOS=7m, OS1yr=14%. 2067 Pre-radiation ACNU-CDDP 87 New GBM mOS=16m, 2015 Sagopilone 38 Recurrent GBM PFS6=9%. 2008 Switching Chemo with Avastin 44 GBM progressed on Avastin mPFS=1.3m, PFS6=2%; not good at all 2014 Talampanel + RT/Temodfar 72 New GBM mOS=17.9m. 2062 Tarceva + rapamycin 27 Recurrent GBM Modest antitumor activity 2016 Tarceva + RT/Temodar 97 New GBM Not better than RT/Temodar (disappointing) 2022 Temodar + VP-16 27 Recurrent GBM "encouraging radiographic response" 2010 Temodar 50mg/m2 daily 120 GBM failing standard Temodar PFS6=7%-35%. 2044 Temodar 7/7 + indomethacin 41 New GBM mPFS=7.6m, PFS6=69%, 1ryOS=70% 2042 Vaccine to cytomegalovirus 21 New GBM mOS>20m.
منابع مشابه
Title: Improving Publication Rates of Biomarker Results from Cancer Trials
In this issue of CLINICAL CANCER RESEARCH, Freeman et. al. assess the frequency of publication of biomarker data derived from mandatory non-diagnostic tumor biopsies, and explore the reasons for non-publication. Their assessment is based on tracking the full publication of AACR and ASCO abstracts identified as including biomarker objectives based on non-diagnostic tumor biopsies. The reasons fo...
متن کاملNeuroendocrine tumors: treatment updates.
Neuroendocrine tumors of the gastroenteropancreatic tract remain a difficult array of neoplasia to treat. Treatment of advanced and metastatic gastroenteropancreatic neuroendocrine tumors has traditionally been difficult with few systemic treatment options. In 2011, two new targeted therapies, everolimus and sunitinib were approved for treatment of pancreatic neuroendocrine tumor. The approval ...
متن کاملHENG and KOLLMANNSBERGER
s+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstractID;=33225; cited January19, 2009]47. Rixe O, Bukowski RM, Michaelson MD, et al. Axitinib treat-ment in patients with cytokine-refractory metastatic renal-cellcancer: a phase ii study. lancet Oncol 2007;8:975–84.48. Hutson TE, Davis ID, Machiels JP, et al. Pazopanib(GW786034) is active in metast...
متن کاملPattern of Duplicate Presentations at National Hematology-Oncology Meetings: Influence of the Pharmaceutical Industry.
PURPOSE The major large US hematology-oncology meetings sponsored by the American Society of Hematology (ASH) and American Society of Clinical Oncology (ASCO) have specific guidelines in place discouraging submission of scientific information presented previously at other meetings. Nonetheless, duplicate submissions are frequent. The incidence and motivations for duplicate hematologic presentat...
متن کاملPharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Among various abstracts presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, June 2010, four interesting abstracts focusing on pancreatic cancer merit further discussion in this post-ASCO commentary as they potentially provide insight to clinicians and hope to patients. These abstracts point to the future of pancreatic cancer management through id...
متن کامل2007 EORTC-NCI-ASCO Annual Meeting: Molecular Markers in Cancer
The recent EORTC-NCI-ASCO Annual Meeting on 'Molecular Markers in Cancer' was held on 15-17 November 2007 in Brussels, Belgium. It was the largest meeting to date and marked the first year in which the American Association of Clinical Oncology (ASCO) joined in the efforts of the European Organisation for Research and Treatment of Cancer (EORTC) and the National Cancer Institute (NCI) in organiz...
متن کامل